Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections

Horowitz, Edward A.; Preheim, Laurel C.; Safranek, Thomas J.; Pugsley, Mary P.; Sanders, Christine C.; Bittner, Marvin J.

doi:10.1128/aac.28.2.299

Cited by 9 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of twenty-seven carumonam-treated patients who could be evaluated, 3 (11%) had adverse laboratory reactions. One reaction was definitely drug related, with marked elevation in liver enzyme levels in (4). However, in a recent study of aztreonam (a monobactam with chemical structure and in vitro activities similar to those of carumonam) for treatment of urinary tract infections in patients with Foley catheters, a superinfection rate higher than that in our study was found.…”

Section: Resultscontrasting

confidence: 53%

Carumonam versus ceftazidime for urinary tract infections

Edelstein¹,

Oster²,

Cassano³

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: Resultscontrasting

confidence: 53%

Carumonam versus ceftazidime for urinary tract infections

Edelstein¹,

Oster²,

Cassano³

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…Clinical trials of parenteral therapy for complicated urinary infection have reported efficacy for a wide variety of agents, but there are limited comparative studies. Aminoglycosides (79,83,86), fluoroquinolones (74,79,85,87), piperacillin/ tazobactam (64,88,89), ceftazidime (74,78,80,82) and carbapenems (61,64,71,82) have all been reported to achieve high rates of clinical and microbiological cure. Duration of therapy: The optimal duration of antimicrobial therapy for the treatment of acute symptomatic episodes has not been systematically studied.…”

Section: Continued On Next Pagementioning

confidence: 99%

Complicated Urinary Tract Infection in Adults

Nicolle¹

2005

Canadian Journal of Infectious Diseases and Medical Microbiolog

216

156

View full text Add to dashboard Cite

OBJECTIVE: To review current knowledge relevant to complicated urinary tract infection, and to provide evidence-based recommendations for management. METHODS: The literature was reviewed through a PubMed search, and additional articles were identified by journal reference review. A draft guideline was prepared and critically reviewed by members of the Association of Medical Microbiology and Infectious Disease Canada Guidelines Committee, with modifications incorporated following the review. RESULTS: Many urological abnormalities may be associated with complicated urinary infection. There is a wide spectrum of potential infecting organisms, and isolated bacteria tend to be more resistant to antimicrobial therapy. Morbidity and infection outcomes in subjects with complicated urinary infection are principally determined by the underlying abnormality rather than the infection. Principles of management include uniform collection of a urine specimen for culture before antimicrobial therapy, characterization of the underlying genitourinary abnormality, and nontreatment of asymptomatic bacteriuria except before an invasive genitourinary procedure. The antimicrobial regimen is determined by clinical presentation, patient tolerance, renal function and known or anticipated infecting organisms. If the underlying abnormality contributing to the urinary infection cannot be corrected, then early post-treatment recurrence of infection is anticipated. CONCLUSIONS: The management of complicated urinary infection is individualized depending on patient variables and the infecting organism. Further clinical investigations are necessary to assist in determining optimal antimicrobial regimens.

show abstract

A multicentre, randomized comparative study of 500 mg versus 1,000 mg ceftazidime t.d.s. for treatment of gram-negative infections

et al. 1995

View full text Add to dashboard Cite

A multicentre, randomized study was performed to compare the clinical and bacteriological efficacy of 500 mg ceftazidime i.v. t.d.s. with 1,000 mg ceftazidime i.v. t.d.s. for treatment of hospitalised, non-compromised patients with gram-negative infections. The study was conducted in ten hospitals in The Netherlands. Hospitalised patients with a suspected gram-negative lower respiratory tract infection, complicated urinary tract infection or septicaemia were included. Excluded were patients with neutropenia, limited life expectancy, or severe renal insufficiency as well as those on antibiotics in the 48 h prior to entry. Ceftazidime was administered via an intravenous infusion every 8 h. For patients with moderately impaired renal function the frequency was reduced to 12 h. Treatment was continued for as long as clinically indicated. Clinical response (cure, improvement or failure) and bacteriological response (elimination, persistence or non-evaluable) were assessed primarily by the investigator. Final assessments were made by a panel of experts without prior knowledge. In total 127 patients were randomized, 64 patients to the 500 mg group and 63 to the 1,000 mg group; 47 patients were excluded from evaluation, usually due to an incorrect diagnosis prior to randomization. Ultimately 37 patients of the 500 mg group and 43 patients of the 1,000 mg group were available for evaluation. Between these two groups of evaluable patients there were no significant differences in baseline characteristics, types of infection, isolated bacterial pathogens or treatment characteristics.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections

Cited by 9 publications

References 14 publications

Carumonam versus ceftazidime for urinary tract infections

Carumonam versus ceftazidime for urinary tract infections

Complicated Urinary Tract Infection in Adults

A multicentre, randomized comparative study of 500 mg versus 1,000 mg ceftazidime t.d.s. for treatment of gram-negative infections

Contact Info

Product

Resources

About